Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide Plus Everolimus in mCRPC After Abiraterone Acetate
NCT02106507Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2014
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of apalutamide in prostate cancer (PCa), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Safety and Tolerability at 2 years, Pharmacokinetics at 2 years and 1 more. Started Apr 2014; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02106507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02106507.